{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:36:43Z","timestamp":1793137003000,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022335","name":"Hospital Cl\u00ednic Barcelona Research Foundation - August Pi i Sunyer Institute of Biomedical Research","doi-asserted-by":"publisher","award":["II040141"],"award-info":[{"award-number":["II040141"]}],"id":[{"id":"10.13039\/501100022335","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030957","name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI20\/00869"],"award-info":[{"award-number":["PI20\/00869"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI20\/00676"],"award-info":[{"award-number":["PI20\/00676"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI24\/00816"],"award-info":[{"award-number":["PI24\/00816"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eclinm.2026.104158","type":"journal-article","created":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T08:49:14Z","timestamp":1787474954000},"page":"104158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reduced-frequency bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV: a single-centre randomised phase 2 pilot trial in Spain"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1959-246X","authenticated-orcid":false,"given":"Iv\u00e1n","family":"Chivite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5913-364X","authenticated-orcid":false,"given":"Elisa","family":"Moraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiu","family":"Sempere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3839-0417","authenticated-orcid":false,"given":"S\u00f2nia","family":"Vicens-Art\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Callau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Hurtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5973-9948","authenticated-orcid":false,"given":"Amedeo","family":"De Nicol\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"S\u00e1nchez-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Blanch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0023-7377","authenticated-orcid":false,"given":"Jos\u00e9","family":"Alcam\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D\u2019Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonsoles","family":"S\u00e1nchez-Palomino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2614-6545","authenticated-orcid":false,"given":"Elisa","family":"De Lazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6911-8846","authenticated-orcid":false,"given":"Esteban","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.104158_bib1","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","article-title":"Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies","volume":"10","author":"Trickey","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.eclinm.2026.104158_bib2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40121-018-0201-6","article-title":"A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population","volume":"7","author":"Chawla","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.eclinm.2026.104158_bib3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40271-023-00641-y","article-title":"Preferences of people living with hiv for long-acting antiretroviral treatment in germany: evidence from a discrete choice experiment","volume":"16","author":"Emmert","year":"2023","journal-title":"Patient"},{"issue":"Supplement_4","key":"10.1016\/j.eclinm.2026.104158_bib4","doi-asserted-by":"crossref","first-page":"S541","DOI":"10.1093\/cid\/ciac716","article-title":"Barriers to uptake of long-acting antiretroviral products for treatment and prevention of human immunodeficiency virus in high-income countries","volume":"75","author":"Cooper","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eclinm.2026.104158_bib5","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(13)62187-X","article-title":"Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.104158_bib6","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/S2352-3018(21)00300-3","article-title":"A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial","volume":"9","author":"Landman","year":"2022","journal-title":"Lancet HIV"},{"key":"10.1016\/j.eclinm.2026.104158_bib7","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.3390\/biomedicines12112620","article-title":"Short-cycle therapy with bictegravir\/emtricitabine\/tenofovir alafenamide in a small cohort of virally suppressed people living with HIV: a long-term follow-up","volume":"12","author":"Lanzafame","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.eclinm.2026.104158_bib8","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1093\/jac\/dkaf186","article-title":"Five-days-on\/two-days-off versus daily bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomised clinical trial","volume":"80","author":"Sun","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eclinm.2026.104158_bib9","first-page":"e02406","article-title":"Long dissociation of bictegravir from HIV-1 integrase-DNA complexes","volume":"65","author":"White","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eclinm.2026.104158_bib10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jac\/dkq447","article-title":"Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection","volume":"66","author":"Anderson","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eclinm.2026.104158_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02038-21","article-title":"Forgiveness of insti-containing regimens at drug concentrations simulating variable adherence in vitro","volume":"66","author":"Acosta","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eclinm.2026.104158_bib12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00002030-200203080-00012","article-title":"Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA study","volume":"16","author":"Knobel","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.eclinm.2026.104158_bib13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","article-title":"A quantitative approach for measuring the reservoir of latent HIV-1 proviruses","volume":"566","author":"Bruner","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.eclinm.2026.104158_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aap9927","article-title":"HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing","volume":"10","author":"Yukl","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eclinm.2026.104158_bib15","first-page":"81","article-title":"Propiedades clinim\u00e9tricas de la versi\u00f3n castellana del Cuestionario de Pittsburgh","volume":"9","author":"Royuela","year":"1997","journal-title":"Vigilia-Sue\u00f1o"},{"key":"10.1016\/j.eclinm.2026.104158_bib16","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s11136-018-1877-5","article-title":"Validity of the EQ-5D-5L and reference norms for the Spanish population","volume":"27","author":"Hernandez","year":"2018","journal-title":"Qual Life Res"},{"key":"10.1016\/j.eclinm.2026.104158_bib17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/ph14010012","article-title":"Validation of a UHPLC-MS\/MS method to quantify twelve antiretroviral drugs within peripheral blood mononuclear cells from people living with HIV","volume":"14","author":"De Nicol\u00f2","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.eclinm.2026.104158_bib18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jpba.2017.02.002","article-title":"UPLC-MS\/MS method for the simultaneous quantification of three new antiretroviral drugs and other antiretroviral agents in human plasma","volume":"138","author":"Simiele","year":"2017","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.eclinm.2026.104158_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107200","article-title":"Plasma, intracellular and lymph node antiretroviral concentrations and HIV DNA change during primary HIV infection: results from the INACTION P25 study","volume":"64","author":"De Nicol\u00f2","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.eclinm.2026.104158_bib20","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3390\/ph14050460","article-title":"Development and validation of a highly sensitive UHPLC-MS\/MS method for the simultaneous quantification of current anti-HIV nucleoside analogues in human plasma","volume":"14","author":"De Nicol\u00f2","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.eclinm.2026.104158_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2018.01.005","article-title":"Establishment of intracellular tenofovir-diphosphate as the key determinant for in vitro\u2013in vivo translation of antiviral efficacy","volume":"151","author":"Ma","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.eclinm.2026.104158_bib22","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2024 recommendations of the International Antiviral Society-USA Panel","volume":"333","author":"Gandhi","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2026.104158_bib23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/QAI.0000000000002562","article-title":"Simulating HIV breakthrough and resistance development during variable adherence to antiretroviral treatment","volume":"86","author":"Mulato","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eclinm.2026.104158_bib24","series-title":"Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide): Epar \u2013 Product Information","year":"2018"},{"key":"10.1016\/j.eclinm.2026.104158_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004006","article-title":"Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men","volume":"4","author":"Anderson","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eclinm.2026.104158_bib26","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cell.2013.09.030","article-title":"Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design","volume":"155","author":"Hendrix","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.eclinm.2026.104158_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003174","article-title":"Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission","volume":"3","author":"Patterson","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eclinm.2026.104158_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac107","article-title":"Dolutegravir monotherapy as maintenance strategy: a meta-analysis of individual participant data from randomised controlled trials","volume":"9","author":"Fournier","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"suppl_3","key":"10.1016\/j.eclinm.2026.104158_bib29","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1093\/infdis\/jiw648","article-title":"Measuring the size of the latent HIV reservoir: the present and future of evaluating eradication strategies","volume":"215","author":"Henrich","year":"2017","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104158_bib30","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132997","article-title":"Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy","volume":"5","author":"Peluso","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.eclinm.2026.104158_bib31","doi-asserted-by":"crossref","first-page":"168","DOI":"10.7326\/ANNALS-25-01939","article-title":"Once-weekly oral islatravir plus lenacapavir versus daily oral bictegravir, emtricitabine, and tenofovir alafenamide in persons with HIV-1 : a phase 2 randomized study","volume":"179","author":"Colson","year":"2026","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104158_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hiv.70231","article-title":"Hepatitis B reactivation in people living with HIV and isolated anti-HBc receiving tenofovir-sparing dual antiretroviral therapy","volume":"27","author":"Arcos-Rueda","year":"2026","journal-title":"HIV Med"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104158_bib33","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1016\/S1473-3099(23)00267-0","article-title":"A partner protection package for HIV cure-related trials involving analytical treatment interruptions","volume":"23","author":"Dub\u00e9","year":"2023","journal-title":"Lancet Infect Dis"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:31:41Z","timestamp":1793136701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026004116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"alternative-id":["S2589537026004116"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104158","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced-frequency bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV: a single-centre randomised phase 2 pilot trial in Spain","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104158"}}